Información sobre riesgo, prevención, detección, síntomas, diagnosis, tratamiento y apoyo para el cáncer.
Información sobre el tratamiento del cáncer incluyendo quirúrgica, quimioterapia, radioterapia, estudios clínicos, terapia con protón, medicina complementaria avanzadas.
OncoLink se complace en ofrecer una amplia lista de lista completa de los agentes quimioterapéuticos más comúnmente usados??. Esta guía de referencia incluye información sobre la forma en que cada fármaco se administra, cómo funcionan, y los pacientes los efectos secundarios comunes pueden experimentar.
Maneras que los pacientes de cáncer y las personas que le cuidan puedan enfrentar el cáncer, los efectos secundarios, nutrición, cuestiones en general sobre el apoyo para el cáncer, duelo/decisiones sobre el termino de vida, y experiencias compartidas por sobrevivientes.
Tipos de Cancer / Cánceres del Hueso / Sarcoma de Ewing / Exámenes de Detección
National Cancer Institute®
Ultima Vez Modificado: 1 de junio del 2002
1
UI - 11990703
AU - Reichardt P; Apel TW; Domula M; Trobs RB; Krause I; Bierbach U; Neumann
TI -
HP; Kiess W
Recurrent polytopic chromaffin paragangliomas in a 9-year-old boy
resulting from a novel germline mutation in the von Hippel-Lindau gene.
SO - J Pediatr Hematol Oncol 2002 Feb;24(2):145-8
AD - Intensive Care Unit, Children's Hospital of the University of Leipzig,
Germany. reichp@medizin.unileipzig.de
Pheochromocytomas are frequently associated with inherited cancer
syndromes such as von Hippel-Lindau disease (VHL). Retinal angioma and
hemangioblastomas of the central nervous system are hallmarks of VHL,
but its clinical variety is remarkably broad. Pheochromocytomas as the
sole or first manifestation of VHL are rare but have been observed. In
this case report, the authors describe an unusual case of initial
collapse, seizures, and hypertensive crisis in a child who later was
found to have multiple extraadrenal pheochromocytomas. Molecular
diagnostics revealed a novel point mutation in the VHL gene (VHL nt. 406
T-->G). Only 7 months after the first lesions had been removed, a new
paraganglioma developed in the contralateral periadrenal region. When
encountering pheochromocytomas in children, the clinician should be
aware that an associated tumor syndrome might be present, and
appropriate molecular screening should be initiated. Molecular genetics
aid in the clinical decision-making and clinical management of
individual patients with pheochromocytoma.
2
UI - 11987607
AU - Biernat W
TI -
[Congenital neoplasms]
SO - Pol J Pathol 2001;52(4 Suppl):191-203
AD - Zaklad Patologii Nowotworow, Katedra Onkologii AM, lodz.
3
UI - 11904337
AU - Duffy K; Al-Saleem T; Karbowniczek M; Ewalt D; Prowse AH; Henske EP
TI -
Mutational analysis of the von hippel lindau gene in clear cell renal
carcinomas from tuberous sclerosis complex patients.
SO - Mod Pathol 2002 Mar;15(3):205-10
AD - Medical Oncology Division, Fox Chase Cancer Center, Philadelphia,
Pennsylvania 19111, USA.
Tuberous sclerosis complex (TSC) is an autosomal-dominant disorder
characterized by seizures, mental retardation, autism, and tumors of
multiple organs. Renal disease in TSC includes angiomyolipomas, cysts,
and renal cell carcinomas. It is known that somatic mutations in the von
Hippel Lindau (VHL) tumor suppressor gene occur in most clear cell renal
carcinomas. To determine whether TSC-associated clear cell carcinomas
also contain VHL mutations, we analyzed six tumors for loss of
heterozygosity in the VHL gene region of chromosome 3p and for mutations
in the VHL gene. Four of the patients were women between the ages of 34
and 68 years, and two were males under the age of 21 years. The loss of
heterozygosity analysis was performed using polymorphic microsatellite
markers, and the mutational analysis was performed using direct
sequencing. Chromosome 3p loss of heterozygosity was not detected, and
no VHL mutations were identified. These findings suggest that mutations
in the TSC1 and TSC2 genes lead to clear cell renal carcinogenesis via
an alternate pathway not involving VHL mutations.
4
UI - 12000816
AU - Neumann HP; Bausch B; McWhinney SR; Bender BU; Gimm O; Franke G;
TI -
Schipper J; Klisch J; Altehoefer C; Zerres K; Januszewicz A; Eng C;
Smith WM; Munk R; Manz T; Glaesker S; Apel TW; Treier M; Reineke M; Walz
MK; Hoang-Vu C; Brauckhoff M; Klein-Franke A; Klose P; Schmidt H;
Maier-Woelfle M; Peczkowska M; Szmigielski C; Eng C; The
Freiburg-Warsaw-Columbus Pheochromocytoma Study Group
Germ-line mutations in nonsyndromic pheochromocytoma.
SO - N Engl J Med 2002 May 9;346(19):1459-66
AD - Department of Nephrology and Hypertension, Albert Ludwigs University,
Freiburg, Germany. neumann@mm41.ukl.uni-freiburg.de
BACKGROUND: The group of susceptibility genes for pheochromocytoma that
included the proto-oncogene RET (associated with multiple endocrine
neoplasia type 2 [MEN-2]) and the tumor-suppressor gene VHL (associated
with von Hippel-Lindau disease) now also encompasses the newly
identified genes for succinate dehydrogenase subunit D (SDHD) and
succinate dehydrogenase subunit B (SDHB), which predispose carriers to
pheochromocytomas and glomus tumors. We used molecular tools to classify
a large cohort of patients with pheochromocytoma with respect to the
presence or absence of mutations of one of these four genes and to
investigate the relevance of genetic analyses to clinical practice.
METHODS: Peripheral blood from unrelated, consenting registry patients
with pheochromocytoma was tested for mutations of RET, VHL, SDHD, and
SDHB. Clinical data at first presentation and follow-up were evaluated.
RESULTS: Among 271 patients who presented with nonsyndromic
pheochromocytoma and without a family history of the disease, 66 (24
percent) were found to have mutations (mean age, 25 years; 32 men and 34
women). Of these 66, 30 had mutations of VHL, 13 of RET, 11 of SDHD, and
12 of SDHB. Younger age, multifocal tumors, and extraadrenal tumors were
significantly associated with the presence of a mutation. However, among
the 66 patients who were positive for mutations, only 21 had multifocal
pheochromocytoma. Twenty-three (35 percent) presented after the age of
30 years, and 17 (8 percent) after the age of 40. Sixty-one (92 percent)
of the patients with mutations were identified solely by molecular
testing of VHL, RET, SDHD, and SDHB; these patients had no associated
signs and symptoms at presentation. CONCLUSIONS: Almost one fourth of
patients with apparently sporadic pheochromocytoma may be carriers of
mutations; routine analysis for mutations of RET, VHL, SDHD, and SDHB is
indicated to identify pheochromocytoma-associated syndromes that would
otherwise be missed.
5
UI - 12016154
AU - Hemminki K; Jiang Y; Ma X; Yang K; Egevad L; Lindblad P
TI -
Molecular epidemiology of VHL gene mutations in renal cell carcinoma
patients: relation to dietary and other factors.
SO - Carcinogenesis 2002 May;23(5):809-15
AD - Department of Biosciences at Novum, Karolinska Institute, 141 57
Huddinge, Sweden. kari.hemminki@cnt.ki.se
Carcinogenic chemicals act through DNA damage and mitogenic effects. No
established mechanism explains the cancer preventive effects, if any, of
food items, such as vegetables and fruit. If such data were available,
preferably on tumor-initiating genes, the evidence for the protective
effects would become stronger. The von Hipple-Lindau (VHL) gene is the
tumor suppressor gene predisposing to both sporadic renal cell carcinoma
(RCC) and von Hippel-Lindau disease. We have earlier analyzed VHL
mutations in RCCs from 102 Swedish patients identified in a case-control
study and here examine associations between patient characteristics,
including dietary habits and mutations, considering the type of
mutation. The results are given as odds ratios (OR), separately for
smokers and all patients. In univariate analysis, consumption of
vegetables and citrus fruit decreased the frequency of VHL mutations
among smokers and citrus fruit among all patients. In multivariate
analysis of smokers' characteristics, welding fumes showed a risk of
5.63 for multiple VHL mutations. In smokers, citrus fruit decreased the
OR of GC to AT mutations to 0.13 and that of multiple mutations to 0.17;
vegetables decreased the OR for single mutations to 0.22. Among all
subjects, welding fumes were a risk factor and citrus fruit a protective
factor. Additionally, an intake of selenium protected against multiple
mutations. The present results provide evidence that the intake of
vegetables, selenium and particularly of citrus fruit protects the renal
VHL gene from mutational insults that may be endogenous or common in a
population. Even though most of the associations are biologically
plausible, and vegetables and fruit were an a priori hypothesis,
fortuitous results cannot be ruled out in this relatively small study.
The above citations and abstracts reflect those newly added to CANCERLIT for the month and topic listed in the title. The citations have been retrieved from CANCERLIT using a predefined search strategy of indexed subject terms. Although the search strategy has been refined as best as possible, citations may appear that are not directly related to the topic, and occasionally relevant references may be omitted.
Dr. Tobey discusses some of the controversy surrounding breast cancer screening with mammography. Read more.
Cancer Types
Bone Cancer
Brain Tumors
Breast Cancer
Carcinoid Tumors
Endocrine System Cancers
Gastrointestinal Cancers
Gynecologic Cancers
Head and Neck Cancers
Leukemia
Lung Cancers
Lymphomas
Myelomas
Pediatric Cancers
Penile Cancer
Prostate Cancer
Sarcomas
Skin Cancers
Testicular Cancer
Thyroid Cancer
Urinary Tract Cancers
OncoLink Vet
Cancer Treatment
Biologic Therapy
Bone Marrow Transplants
Chemotherapy
Clinical Trials
Complementary Medicine
Gene Therapy
General Treatment Concerns
Hormone Therapy
PDT Center
Proton Therapy
Radiation Oncology
Surgical Oncology
Targeted Therapies
Vaccine Therapies
Cancer Support
Caregivers
Hospice Care and Bereavement
Nutrition and Cancer
Sexuality & Fertility
Side Effects
Support
Survivorship
Exercise and Cancer
Cancer Resources
Cancer News
OncoLink University
Nurses' Notes
Conferences
Newly Diagnosed Patients
Causes and Prevention
Legal and Financial Information for Patients
LGBT Resources
NCI Resources
Global Resources
Cancer Resource List
Resources for Young Adults
OncoLink Media Library
OncoLink TV
Book, Music and Video Reviews
Ask the Experts
Brown Bag Chat
Tracy's Corner
About OncoLink
About OncoLink
Giving to OncoLink
Contact Information
Usage Policy
Editorial Board
How to Partner with OncoLink
Link to OncoLink
Mission Statement
Calcium Leucovorin, Citrovorum Factor, Folinic Acid
Cladribine (2-CDA, Leustatin®)
Cyclophosphamide (Cytoxan®, Neosar®, Endoxan®)
Cyclosporine (Neoral®, Sandimmune®, Restasis®, Gengraf®)
Cytarabine (Cytosar-U®, Ara-C)
Irinotecan (Camptosar®, CPT-11)
Leucovorin (Calcium Leucovorin, Citrovorum Factor, Folinic Acid)
Calcium Leucovorin, Citrovorum Factor, Folinic Acid
Leucovorin (Calcium Leucovorin, Citrovorum Factor, Folinic Acid)
Leuprolide Acetate (Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®) - For Men
Leuprolide Acetate (Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®) - For Women
Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®
Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®
Busulfan (Myleran®, Busulfex®)
Intravesicular Mitomycin (Mutamycin®, Mitomycin-C, given into the bladder)
Mechlorethamine (Mustargen®, Nitrogen Mustard)
mechlorethamine, mustine, Mustargen®
Megestrol (Megace®, Megace-ES®)
Mercaptopurine (Purinethol®, 6-MP)
Methotrexate (Mexate®, Folex®, Rheumatrex®, Amethopterin, MTX)
Mexate®, Folex®, Rheumatrex®, Amethopterin, MTX
Mitomycin (Mutamycin®, Mitomycin-C)
Morphine Sulfate (Given by IV)
Morphine Sulfate (MS Contin®, Avinza®, Kadian®, Oramorph SR®)
MS Contin®, Avinza®, Kadian®, Oramorph SR®
Mutamycin®, Mitomycin-C, given into the bladder
Nitrogen mustard (mechlorethamine, mustine, Mustargen®)
Bendamustine Hydrochloride (Treanda®)
Bexarotene (Targretin®), Oral Formulation
Bexarotene Gel (Targretin® Gel Formulation)
Etoposide (Toposar®, VePesid®, Etopophos®,VP-16)
Thioguanine (6-TG, Thioguanine Tabloid®)
Toposar®, VePesid®, Etopophos®,VP-16
Trelstar LA® and Trelstar Depot®
Tretinoin (Vesanoid®, All-Trans-Retinoic Acid, ATRA)
Triptorelin (Trelstar LA® and Trelstar Depot®)

